Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

Lena Marshall

184 stories · Page 2 of 8

Cancer

Hengrui's Breast Cancer Drug More Than Doubled Progression-Free Survival While Severe Anemia Hit Four in Ten Patients

Trastuzumab rezetecan pushed median progression-free survival to 16.4 months from 6.8 on chemotherapy in 551 patients, all treated in China, while grade 3 or worse anemia reached 42.8 percent against 4.8 percent.

Drugs & FDA

Six Months Against Twelve: How Essilor's New Myopia Lens Got Called 'Twice as Fast'

Stellest 2.0's six-month numbers sat close to the original lens's one-year result from a separate trial, and a company symposium in London called that twice as fast. The children's lens is on sale abroad and has not been cleared by the FDA.

Brain & Aging

Psilocybin Trial's Banked Blood Shows Parkinson's Inflammation Markers Still Lower a Month Later

Five inflammatory signals were still below baseline a month after the second psilocybin session, in blood banked from nine Parkinson's patients in an uncontrolled UCSF pilot whose investigators carry psychedelic-industry ties.

Cancer

The Vitamin C Trial That Missed Its Goal and Counted 11 Deaths Against 24

Copenhagen and USC researchers gave 1,000 mg of plain vitamin C a day to people with pre-leukemic blood disorders. The mutant clones grew regardless, but over three years of follow-up 11 patients assigned to the vitamin died, against 24 assigned to placebo.

Drugs & FDA

GSK's Hepatitis B Drug Got a Label That Reaches Patients It Functionally Cured About One Time in 14

Below 1,000 IU/mL of surface antigen, 26 percent of treated patients reached functional cure. Between 1,000 and 3,000, a range the FDA's label also covers, GSK's own counts work out to about 7 percent, for a weekly injection boxed for serious liver reactions and low platelets.

Investigations

A Melbourne Gender Study Scored 234 Children on Their Transition Goals and Left Wellbeing Out

Researchers at Melbourne's Royal Children's Hospital sorted 234 children aged 8 to 17 by how many of their name, pronoun and appearance goals they had reached. Their cohort tracks mental health, and the paper did not analyze it as an outcome.

Cancer

The Number Behind GSK's Rectal Cancer Approval Is 47 Percent, Not 76

Independent reviewers confirmed a year-long complete response in 54 of 116 AZUR-1 patients. GSK's release also carried an exploratory 76 percent. For a narrow slice of rectal cancer patients, the drug may still spare them radiation and surgery.

Drugs & FDA

The FDA Fast-Tracked GSK's Rectal Cancer Drug and Left the Trial's Own Scorecard Out of Its Announcement

Independent reviewers found 47 percent of evaluable AZUR-1 patients held a complete response for a year, the trial's registered endpoint. The FDA's announcement quoted friendlier measures instead.

Nutrition & Food

Vitamin D2 Supplements Lower the Vitamin D3 Already in Your Blood

Pooling randomized trials, Surrey researchers found people taking vitamin D2 ended up with less circulating vitamin D3, the form sunlight makes, than people who took none, by as much as 18 nmol/L.

Cancer

To Keep Cancer-Fighting Cells Alive, a Sloan Kettering Lab Wants Them to Fight Less Hard

Memorial Sloan Kettering researchers say throttling exhausted T cells with a drug class already used against melanoma may keep them alive longer. So far the evidence comes only from lab and animal models.

Investigations

The WHO Asked the World to Listen to Mental Health Patients. By Its Own Count, Half Were Committed Against Their Will.

The WHO built this year's World Mental Health Day around putting patients in charge of policy. Its own 2024 atlas reports 49% of reported admissions are involuntary and nearly a quarter of hospital stays run past a year.

Cancer

The Urine Test That Could Retire the Bladder Scope Already Has a Startup Behind It

Stanford's uRARE-seq caught 95 percent of localized bladder cancers in a case-control study and nearly tripled cytology's hit rate. It has not faced a prospective trial, and its lead author holds a stake in the spinout commercializing it.

Cancer

The Sepsis Drug Eli Lilly Withdrew in 2011 Has a Second Life in a Dish of Blood Stem Cells

Soaked in activated protein C for one hour, human blood stem cells divided less, stayed quiescent, and engrafted better after transplant. The catch: the result lives in mice, and the molecule is one Eli Lilly withdrew as a failed sepsis drug in 2011.

Cancer

The Glioblastoma Trial No Drug Company Paid For Posted an 82% Six-Month Progression-Free Rate

Calgary oncologists bought controlled-release niacin at retail, added it to standard treatment, and cleared their own preset bar with room to spare. The trial is small, single-arm and untidy on paper, and it was paid for entirely with grant money.

Drugs & FDA

The First-Line Glaucoma Drop That Flatters Its Own Pressure Reading

Across 128 eyes followed at one VA clinic, the corneas that thinned most on prostaglandin drops made the pressure gauge read 3.3 mm Hg low, and those eyes lost visual field nearly twice as fast.

Metabolic & Weight

The Cells That Should Heal a Diabetic Wound Are Keeping It Open

The immune cells meant to close a diabetic ulcer get stuck attacking it instead, a Shanghai review argues. It maps the biology in detail, then concedes its central framework is contested and the fixes it points to have never been tested in a person.

Cancer

Ketamine Failed Its Only Adequately Powered Cancer-Pain Trial, and Palliative Care Still Reaches for It

Ketamine's one adequately powered trial in advanced cancer pain found no benefit over placebo, more toxicity and worse quality of life. Fourteen years on, a 2026 review still tells clinicians to consider it.

Brain & Aging

Drugs Aimed at This Week's Brain-Inflammation Target Have Already Failed in Patients

AstraZeneca and Pfizer each took a P2X7 blocker into rheumatoid arthritis trials, and neither beat placebo. A Birmingham lab now says the same receptor could tame inflammation in Alzheimer's and Parkinson's.

Cancer

Cat Breast Tumors Mirror Ours Genetically, and the Cure Talk Never Left the Dish

Almost 500 pet cats supplied tumors for the first large-scale map of feline cancer genes. Every claim about treating people still rests on cat tissue grown in a lab.

Drugs & FDA

A Hundred Thousand Dollars, Two Inches, and a New Calculator for Sorting Short Children

About $100,000 buys a healthy short child two inches of height. A new calculator predicts who responds best, and it joins a field where some of the biggest datasets belong to the companies selling the hormone.

Drugs & FDA

GenSight's Blindness Gene Therapy Reached the NEJM on the Same Day It Reported €0.7 Million in Cash

Seven of ten patients blinded by retinitis pigmentosa sensed more light through special goggles after one gene injection, in an uncontrolled trial whose sponsor held €0.7 million on September 30 and warned it may not survive the year.

Drugs & FDA

FDA's Anktiva Approval for Papillary-Only Bladder Cancer Cites No Papillary-Only Patients

Seventeen months after refusing even to review ImmunityBio's application, the FDA expanded Anktiva's label by extrapolating from carcinoma in situ, and its announcement never mentioned the 80 papillary-only patients the company had actually studied.

Cancer

Cancer Wasting Was Hiding in Two Million Routine Weigh-Ins

At Memorial Sloan Kettering, 48.8% of 59,493 tumor-sequenced cancer patients had at least one cachectic weight-loss episode over about five years. No drug is approved for it, and a French hospital coded it in under 1% of its cancer patients.

Drugs & FDA

A Heart-Failure Implant Won by 40 Points on a Questionnaire Filled Out by Patients Who Knew Which Arm They Were In

Patients given Berlin Heals' microcurrent implant reported quality-of-life gains eight times the control arm's in an open-label trial. The blood marker and exercise test that could have backed them up showed no significant difference, and the company paid for the study.